Rhabdomyolysis or Severe Acute Hepatitis Associated with the Use of Red Yeast Rice Extracts: an Update from the Adverse Event Reporting Systems

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review

(2023) Arrigo F. G. Cicero et al.   Nutrients

Statin-induced Liver Injury Patterns: A Clinical Review

(2022) Leon D. Averbukh et al.   Journal of Clinical and Translational Hepatology

Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications

(2022) Massimiliano Ruscica et al.   CARDIOVASCULAR RESEARCH

Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis

(2022) Masayuki Chuma et al.   CLINICAL INFECTIOUS DISEASES

Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

(2022) Peter E. Penson et al.   Journal of Cachexia Sarcopenia and Muscle

Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel

(2022) Maciej Banach et al.   PHARMACOLOGICAL RESEARCH

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

(2022) Maciej Banach et al.   Cardiovascular Diabetology

HMG-CoA reductase inhibitors (Statins) and their Drug Interactions involving CYP enzymes, P-glycoprotein and OATP Transporters - An Overview

(2021) Rajkapoor Balasubramanian et al.   CURRENT DRUG METABOLISM

Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia

(2021) Maciej Banach et al.   Archives of Medical Science

Red Yeast Rice for Hypercholesterolemia

(2021) Arrigo F.G. Cicero et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Review of Red Yeast Rice, a Traditional Fermented Food in Japan and East Asia: Its Characteristic Ingredients and Application in the Maintenance and Improvement of Health in Lipid Metabolism and the Circulatory System

(2021) Hiroyuki Fukami et al.   MOLECULES

Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients

(2021) John W Davis et al.   BMJ Open

Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta‐analysis

(2021) Masaru Samura et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Narrative Review of Statin-Induced Rhabdomyolysis: Molecular Mechanism, Risk Factors, and Management

(2021) Nisa Safitri et al.   Drug Healthcare and Patient Safety

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials

(2019) Federica Fogacci et al.   PHARMACOLOGICAL RESEARCH

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

A comprehensive review on biological properties of citrinin

(2017) José Williams Gomes de Oliveira Filho et al.   FOOD AND CHEMICAL TOXICOLOGY

Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention

(2016) Tina Heinz et al.   NUTRITION RESEARCH

Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – A systematic review and meta-analysis

(2015) Maaike C. Gerards et al.   ATHEROSCLEROSIS

Symptomatic Hepatitis Associated with the Use of Herbal Red Yeast Rice

(2013) Harry Roselle et al.   ANNALS OF INTERNAL MEDICINE

Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products

(2013) Chia-Hao Chen et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

OATP1B1-related drug–drug and drug–gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis

(2013) Bani Tamraz et al.   Pharmacogenetics and Genomics

Drug induced rhabdomyolysis

(2012) Martin Hohenegger   CURRENT OPINION IN PHARMACOLOGY

Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin

(2012) Chia-Hao Chen et al.   Evidence-based Complementary and Alternative Medicine

Characteristics of Drug-Associated Rhabdomyolysis: Analysis of 8,610 Cases Reported to the U.S. Food and Drug Administration

(2011) Yasuo Oshima   INTERNAL MEDICINE

Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing

(2011) Einar Björnsson et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Acute hepatitis caused by a natural lipid-lowering product: When “alternative” medicine is no “alternative” at all

(2009) Antonio Grieco et al.   JOURNAL OF HEPATOLOGY